PerkinElmer
check quantity

PCSK9/LDLR (human) AlphaLISA Binding Kit, 500 Assay Points

This kit is designed to assess binding and inhibition of human PCSK9 and LDLR, using a homogeneous AlphaLISA assay (no wash steps). This assay can facilitate the design and development of antibody therapetics using competition assays.

For research use only. Not for use in diagnostic procedures.

Part Number
Unit Size
List Price
Your Price
Quantity
AL3119C
500 Assay Points
2502.00 USD
 
more
AL3119F
5,000 Assay Points
17900.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Detail Information

The AlphaLISA® human PCSK9 and human LDLR binding assay uses anti-6xHis AlphaLISA Acceptor beads to capture the His-tagged PCSK9 and Streptavidin-coated Donor beads to capture the biotinylated LDLR. When PCSK9 binds LDLR, excitation of the Donor beads provokes the release of singlet oxygen that triggers a cascade of energy transfer reactions in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Formats:

  • Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 20 µL reaction volume.
  • Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 20 µL reaction volume.

AlphaLISA features:

  • No-wash steps, no separation steps
  • Ease-of-use: few addition steps, fast assay development
  • Broad range of affinities: detect strong or weak interactions, from pM to mM affinity
  • Distance: measure very large protein or antibody complexes – spanning up to 200 nm or more
  • High avidity: multiple binding sites on each bead enables use of nanomolar concentrations of antibodies or proteins, as well as use of low affinity binders

Human proprotein convertase subtilisin/kexin type 9 (PCSK9), also known as FH3, HCHOLA3, NARC1 and PC9, is a crucial player in the regulation of plasma cholesterol homeostasis. PCSK9 binds to low density lipoprotein receptor (LDLR) and promotes PCSK9 lysosomal degradation in the liver, thereby reducing LDL clearance. Studies of PCSK9-LDLR binding have aided in the development of therapeutic anti-PCSK9 antibodies that effectively block this interaction at the cell surface. Therefore, blocking PCSK9 and LDLR binding has been considered a promising therapeutic target against cardiovascular disease.

Specifications

Assay Target PCSK9,LDLR
Assay Target Class Protein
Automation Compatible Yes
Detection Method Alpha
Product Brand Name AlphaLISA
Shipping Condition Blue Ice
Target Species Human
Therapeutic Area Cardiovascular
Unit Size 500 Assay Points
Resources, Events & More
  • All

Application Note

Evaluating the Specificity of PD-1 and PD-L1 Blocking Antibodies Using AlphaLISA Human and Mouse PD-1/PD-L1 Binding Kits

Mouse pharmacological models continue to play a large role in the study of human disease, and mouse tool reagents have shown high utility in immunology and cancer research for decades. It can often be quicker to learn about immunology and the regulation of immune responses using a syngeneic mouse model. However, working in mouse systems can often require the development of separate mouse reagents, if the therapeutic agent of interest does not cross-react with mouse. Find out how the AlphaLISA® human PD-1/PD-L1 and AlphaLISA mouse PD-1/PD-L1 binding assays provide a fast, powerful, homogeneous platform for obtain binding potencies from potential novel drug candidates.

PDF 1 MB